Kyle Simon D, Miller Christopher B, Rogers Zoe, Siriwardena A Niroshan, Macmahon Kenneth M, Espie Colin A
School of Psychological Sciences, University of Manchester, Manchester, UK.
Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.
Sleep. 2014 Feb 1;37(2):229-37. doi: 10.5665/sleep.3386.
To investigate whether sleep restriction therapy (SRT) is associated with reduced objective total sleep time (TST), increased daytime somnolence, and impaired vigilance.
Within-subject, noncontrolled treatment investigation.
Sleep research laboratory.
Sixteen patients [10 female, mean age = 47.1 (10.8) y] with well-defined psychophysiological insomnia (PI), reporting TST ≤ 6 h.
Patients were treated with single-component SRT over a 4-w protocol, sleeping in the laboratory for 2 nights prior to treatment initiation and for 3 nights (SRT night 1, 8, 22) during the acute interventional phase. The psychomotor vigilance task (PVT) was completed at seven defined time points [day 0 (baseline), day 1,7,8,21,22 (acute treatment) and day 84 (3 mo)]. The Epworth Sleepiness Scale (ESS) was completed at baseline, w 1-4, and 3 mo.
Subjective sleep outcomes and global insomnia severity significantly improved before and after SRT. There was, however, a robust decrease in PSG-defined TST during acute implementation of SRT, by an average of 91 min on night 1, 78 min on night 8, and 69 min on night 22, relative to baseline (P < 0.001; effect size range = 1.60-1.80). During SRT, PVT lapses were significantly increased from baseline (at three of five assessment points, all P < 0.05; effect size range = 0.69-0.78), returning to baseline levels by 3 mo (P = 0.43). A similar pattern was observed for RT, with RTs slowing during acute treatment (at four of five assessment points, all P < 0.05; effect size range = 0.57-0.89) and returning to pretreatment levels at 3 mo (P = 0.78). ESS scores were increased at w 1, 2, and 3 (relative to baseline; all P < 0.05); by 3 mo, sleepiness had returned to baseline (normative) levels (P = 0.65).
For the first time we show that acute sleep restriction therapy is associated with reduced objective total sleep time, increased daytime sleepiness, and objective performance impairment. Our data have important implications for implementation guidelines around the safe and effective delivery of cognitive behavioral therapy for insomnia.
探讨睡眠限制疗法(SRT)是否与客观总睡眠时间(TST)减少、日间嗜睡增加及警觉性受损有关。
受试者内非对照治疗研究。
睡眠研究实验室。
16例患者[10名女性,平均年龄=47.1(10.8)岁],患有明确的心理生理性失眠(PI),报告TST≤6小时。
患者在4周的方案中接受单组分SRT治疗,在治疗开始前在实验室睡2晚,在急性干预阶段睡3晚(SRT第1、8、22晚)。在七个特定时间点[第0天(基线)、第1、7、8、21、22天(急性治疗)和第84天(3个月)]完成精神运动警觉任务(PVT)。在基线、第1 - 4周和3个月时完成爱泼沃斯嗜睡量表(ESS)。
SRT前后主观睡眠结果和整体失眠严重程度显著改善。然而,在SRT急性实施期间,PSG定义的TST显著下降,相对于基线,第1晚平均减少91分钟,第8晚减少78分钟,第22晚减少69分钟(P<0.001;效应量范围=1.60 - 1.80)。在SRT期间,PVT失误次数从基线显著增加(在五个评估点中的三个,均P<0.05;效应量范围=0.69 - 0.78),到3个月时恢复到基线水平(P = 0.43)。反应时间(RT)也观察到类似模式,急性治疗期间RT减慢(在五个评估点中的四个,均P<0.05;效应量范围=0.57 - 0.89),3个月时恢复到治疗前水平(P = 0.78)。ESS评分在第1、2和3周时升高(相对于基线;均P<0.05);到3个月时,嗜睡已恢复到基线(正常)水平(P = 0.65)。
我们首次表明,急性睡眠限制疗法与客观总睡眠时间减少、日间嗜睡增加及客观行为表现受损有关。我们的数据对失眠认知行为疗法安全有效实施的指导方针具有重要意义。